Free tool
FAERS Monitor: Conjupri
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212895 or its brand name (Conjupri, Levamlodipine Maleate). Reports on generic versions are filed under their own applications.
Reports
125
Serious
119
95% of reports
Hospitalization
74
Death reported
14
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea12
- fatigue8
- hypertension8
- nausea8
- pain8
- arthralgia7
- drug ineffective7
- hypoaesthesia7
- malaise7
- pneumonia7
- constipation6
- decreased appetite6
- dyspnoea6
- off label use6
- pain in extremity6
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 2 |
| 2013 | 5 |
| 2014 | 10 |
| 2015 | 1 |
| 2016 | 10 |
| 2017 | 10 |
| 2018 | 20 |
| 2019 | 11 |
| 2020 | 9 |
| 2021 | 10 |
| 2022 | 8 |
| 2023 | 9 |
| 2024 | 5 |
| 2025 | 9 |
| 2026 | 6 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,034 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypoaesthesiaSignal | 7 | 7.9 | 3.8 | 36 |
| hypertensionSignal | 8 | 6.4 | 3.3 | 31 |
| constipationSignal | 6 | 4.6 | 2.1 | 14 |
| decreased appetiteSignal | 6 | 4.3 | 2.0 | 12 |
| pneumoniaSignal | 7 | 3.6 | 1.8 | 11 |
| pain in extremitySignal | 6 | 3.4 | 1.6 | 8 |
| diarrhoeaSignal | 12 | 3.1 | 1.8 | 16 |
| arthralgiaSignal | 7 | 2.8 | 1.4 | 7 |
| malaiseSignal | 7 | 2.7 | 1.3 | 6 |
| painSignal | 8 | 2.2 | 1.1 | 4 |
| dyspnoea | 6 | 1.8 | 0.8 | 1 |
| fatigue | 8 | 1.7 | 0.9 | 2 |
| nausea | 8 | 1.7 | 0.9 | 2 |
| off label use | 6 | 1.2 | 0.5 | 0 |
| drug ineffective | 7 | 0.9 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.